Payment overview · 2025
General Payments
$1,281.35
69 reported records · 24 companies
Healthcare provider profile · identity verified
William T Boulware, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIBERTY, MO · NPI 1023190493
Verified facts
What the public records show
CMS Open Payments records show William T Boulware, MD received $1,281.35 in general payments during 2025 across 69 reported records.
Amgen Inc. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.84 | 16.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.76 | 12.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.73 | 7.3% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $88.45 | 6.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.04 | 6.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $64.64 | 5.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.12 | 4.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $57.18 | 4.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.15 | 4.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.96 | 3.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.70 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.65 | 3.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.32 | 2.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.23 | 2.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.88 | 2.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.10 | 2.3% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $24.73 | 1.9% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $21.32 | 1.7% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $19.68 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.63 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.16 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.79 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.59 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.70 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,281.35 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $207.84 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $207.84 | 13 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $88.45 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $83.71 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.87 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $64.64 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $57.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.79 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.43 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.43 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| HYMHYN Normalized: hymhyn |
Device | Fidia Pharma USA Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 77 |
| Omeprazole | Omeprazole | 303 | 82 |
| Ezetimibe | Ezetimibe | 239 | 67 |
| Eliquis | Apixaban | 236 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 64 |
| Famotidine | Famotidine | 218 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 216 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 57 |
| Alprazolam | Alprazolam | 195 | 48 |
| Prednisone | Prednisone | 190 | 87 |
| Gabapentin | Gabapentin | 187 | 46 |
| Bumetanide | Bumetanide | 162 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 41 |
| Potassium Chloride | Potassium Chloride | 155 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 45 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 136 | 77 |
| Spironolactone | Spironolactone | 131 | 30 |
| Ozempic | Semaglutide | 116 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 102 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 26 |
| Finasteride | Finasteride | 96 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 21 |
| Trazodone Hcl | Trazodone Hcl | 90 | 26 |
| Clonazepam | Clonazepam | 89 | 12 |
| Jardiance | Empagliflozin | 89 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 18 |
| Pregabalin | Pregabalin | 87 | 16 |
| Lisinopril | Lisinopril | 86 | 24 |
| Cephalexin | Cephalexin | 82 | 50 |
| Losartan Potassium | Losartan Potassium | 82 | 29 |
| Montelukast Sodium | Montelukast Sodium | 82 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 47 |
| Carvedilol | Carvedilol | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 19 |
| Metformin Hcl Er | Metformin Hcl | 80 | 29 |
| Raloxifene Hcl | Raloxifene Hcl | 80 | 14 |
| Meloxicam | Meloxicam | 76 | 26 |
| Allopurinol | Allopurinol | 75 | 18 |
| Donepezil Hcl | Donepezil Hcl | 75 | 12 |
| Metformin Hcl | Metformin Hcl | 71 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 70 | 11 |
| Mounjaro | Tirzepatide | 69 | 12 |
| Temazepam | Temazepam | 68 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 17 |
| Entresto | Sacubitril/Valsartan | 66 | 16 |
| Tramadol Hcl | Tramadol Hcl | 66 | 17 |
| Azithromycin | Azithromycin | 64 | 47 |
| Celecoxib | Celecoxib | 62 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 12 |
| Ketoconazole | Ketoconazole | 61 | 24 |
| Sertraline Hcl | Sertraline Hcl | 61 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 59 | 15 |
| Lorazepam | Lorazepam | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Irbesartan | Irbesartan | 53 | suppressed |
| Modafinil | Modafinil | 51 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 12 |
| Cefdinir | Cefdinir | 50 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 25 |
| Colestipol Hcl | Colestipol Hcl | 47 | 14 |
| Myrbetriq | Mirabegron | 47 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 47 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 15 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 45 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 12 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Telmisartan | Telmisartan | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 38 | suppressed |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 14 |
| Furosemide | Furosemide | 37 | suppressed |
| Linzess | Linaclotide | 37 | 14 |
| Memantine Hcl Er | Memantine Hcl | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Testosterone | Testosterone | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 14 |
| Atenolol | Atenolol | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 31 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 19 |
| Torsemide | Torsemide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Levofloxacin | Levofloxacin | 27 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 22 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 23 | suppressed |
| Alprazolam Er | Alprazolam | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 12 |
| Diazepam | Diazepam | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 12 |
| Primidone | Primidone | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,281.35 · 69 records | Amgen Inc. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, HYMHYN, INSPIRE, JARDIANCE, KISUNLA, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Sunosi, Symbravo, TONMYA, Tyenne, UBRELVY, VIBERZI, VOQUEZNA, VYEPTI, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error